Psychedelics in depression

Article written and reviewed by Dr Luca Moretti

Classic psychedelics include substances such as psilocybin, LSD and DMT, characterized mainly by agonism or partial agonism at serotonergic 5-HT2A receptors and the ability to produce profound transient changes in perception, self-experience and cognition. They should not be confused with ketamine, which is an NMDA-receptor antagonist dissociative, or with MDMA, generally classified as an entactogen with predominantly monoaminergic pharmacology. In depression, Psilocybin is the psychedelic with the most advanced clinical research program.

Results from several randomized trials indicate a rapid and sometimes prolonged reduction in depressive symptoms after one or a few psilocybin sessions within highly structured protocols involving preparation, supervised administration and psychological support. These data are promising, including in treatment-resistant depression, but they do not demonstrate efficacy in unsupervised use. As of August 19, 2026, there is no psilocybin-based product approved by the FDA for depression in the United States; in July 2026 the FDA published final guidance dedicated to the clinical development of psychedelic drugs, confirming that the field remains under regulatory investigation.

Pharmacology of classic psychedelics

Psilocybin is a prodrug rapidly converted to psilocin, which interacts with several serotonergic receptors, particularly 5-HT2A. Activation of these receptors in the cortex alters network dynamics, with a transient increase in the diversity of activity patterns, changes in functional connectivity and changes in the relationship between associative networks. Effects on cognitive and emotional flexibility and plasticity processes have been proposed, but a causal link between any specific neurobiological change and clinical remission has not yet been demonstrated.

LSD shares 5-HT2A activity but has longer pharmacokinetics and broader receptor interactions. Modern depression-specific data are much less developed than those for psilocybin. DMT has a very short duration when administered without monoamine oxidase inhibition; in ayahuasca it is combined with beta-carbolines that reversibly inhibit MAO-A and allow oral activity. This combination substantially changes the interaction and safety profile and cannot be treated as equivalent to psilocybin.

Acute pharmacology produces perceptual, emotional and cognitive changes that make context part of safety. “Set and setting” describes the influence of expectations, mental state, environment and the relationship with facilitators on the experience, but it should not be used as a magical explanation of efficacy. In modern trials, psychological support is standardized to varying degrees, and the specific contribution of the drug relative to relational components remains an important methodological question.

Psilocybin in major depression

Randomized trials in adults with major depressive disorder have shown clinically relevant reductions on depression rating scales after psilocybin administration with psychological support. The study by Davis and colleagues compared immediate treatment with a wait-list condition and observed rapid symptom reduction. The trial by Raison and colleagues, using a controlled single-dose design, provided further evidence of acute efficacy in a population with major depression.

The comparison between psilocybin and escitalopram attracted particular attention. In the trial by Carhart-Harris and colleagues, the primary endpoint did not show a statistically significant difference between groups; several secondary endpoints favored psilocybin, but they were not adjusted for multiple comparisons and should be interpreted as exploratory. Presenting the study as definitive evidence that psilocybin is superior to SSRIs would therefore be incorrect.

Duration of benefit is variable. Prospective follow-up of small samples has documented improvements lasting for months in some participants, but these studies do not demonstrate that one or two doses reliably prevent relapse in the general population. The need for booster sessions, the role of subsequent psychotherapy and the optimal maintenance strategy remain undefined.

Treatment-resistant depression and single- or repeated-dose studies

In treatment-resistant depression, the multicenter study by Goodwin and colleagues compared several single doses of psilocybin with psychological support: the highest dose studied produced improvement at three weeks compared with the lowest control dose, but adverse events were observed and the duration of benefit was not uniform. Subsequent programs have evaluated repeated administrations and more flexible strategies.

A randomized trial published in 2024 studied one or two psilocybin administrations in assisted psychotherapy for treatment-resistant depression, helping clarify the feasibility and effect of repeated doses. These results are important for clinical development but do not yet define a standard routine-practice protocol. Treatment resistance is also a heterogeneous construct: the number and adequacy of failed treatments, comorbidities and episode duration influence prognosis.

Studies often exclude people with bipolar disorder, a personal or family history of psychosis, high medical risk and numerous comorbidities. Consequently, safety observed in trials cannot be indiscriminately extrapolated to patients who have these very conditions in clinical practice.

Ayahuasca and other psychedelics

A randomized trial of ayahuasca showed a rapid antidepressant effect in patients with treatment-resistant depression. The result supports scientific interest in DMT and beta-carboline-containing preparations, but the product studied has complex pharmacology and is not interchangeable with psilocybin or isolated DMT. MAO-A inhibition increases the potential for interactions with drugs and substances acting on monoaminergic systems.

For LSD and other classic psychedelics, modern evidence specifically addressing antidepressant efficacy is more limited. It is therefore inappropriate to speak of “psychedelics” as though they were a class with uniformly demonstrated clinical efficacy. Each molecule requires separate evaluation of formulation, dose, setting, efficacy and safety.

Microdosing and repeated use of subperceptual doses should not be confused with the therapeutic protocols studied. Controlled evidence on microdosing is insufficient to recommend it as a treatment for depression, and unsupervised use involves problems of substance purity, dosing, interactions and lack of clinical screening.

Ayahuasca is pharmacologically different from psilocybin because it combines compounds containing DMT with beta-carbolines that inhibit monoamine oxidase A and make DMT orally active. This combination introduces specific problems of preparation standardization and drug interactions, in addition to autonomic and gastrointestinal effects. The randomized trial in treatment-resistant depression provided a rapid antidepressant signal, but in a relatively small sample and with a defined experimental formulation and setting. It is therefore incorrect to extrapolate that result to artisanal or ritual preparations or products of uncertain composition. For LSD, isolated DMT and other compounds, clinical antidepressant evidence remains even more limited and does not support routine recommendations.

Methodological limitations of trials

Psychedelic research presents distinctive experimental problems. Subjective effects make it difficult to maintain blinding: patients and therapists may infer allocation, amplifying expectations and behavioral differences during sessions. Active comparators may reduce but not eliminate this problem. Part of the observed effect sizes may therefore reflect a combination of pharmacological effect, expectancy, participant selection and support intensity.

Participants are often highly motivated, open to psychedelic experiences and treated in specialist centers. This limits generalizability. In addition, different protocols use different amounts of preparation, numbers of therapists, hours of support and subsequent integration. If future treatment includes a mandatory psychotherapeutic component, it will be necessary to establish which elements are essential and how training and quality can be ensured at scale.

Another difficulty concerns the multiplicity of endpoints and follow-up. Rapid improvements are clinically relevant, but depression is often recurrent; data are needed on persistence of remission, relapse, repeated exposure, cognitive effects and safety in larger populations.

An additional limitation is participant selection. Many studies exclude bipolar disorder, psychosis, major medical comorbidities, high suicide risk and problematic substance use; samples may also consist of highly motivated people with favorable expectations toward psychedelics. This results in lower external validity than would be required for routine practice. The intensity of psychological support also varies across studies, making it difficult to determine how much of the outcome depends on the drug, the therapeutic context or their interaction. Pragmatic trials and credible comparators are therefore needed, together with longer follow-up and more representative populations.

Patient selection and preparation

In trials, selection includes diagnostic assessment, a history of mania or psychosis, family history of psychotic or bipolar disorders, suicide risk, substance use, cardiovascular disease, pregnancy and concomitant medications. The rationale is not merely regulatory: psychedelics can transiently increase blood pressure and heart rate and can produce intense emotional and perceptual activation.

Management of concomitant antidepressants is complex because some drugs may alter the psychedelic experience and interactions may depend on the substance. Generic discontinuation rules are inappropriate: tapering or stopping antidepressants can cause withdrawal symptoms and relapse and should be decided only within a clinical or experimental protocol.

Psychological preparation in trials is intended to establish realistic expectations, explain possible experiences, define strategies for managing anxiety and loss of control, and build a safe relationship with the team. After administration, integration sessions help process material that emerged during the experience. The specific value of these components remains under study, but their presence in trials prevents results from being equated with recreational or unsupervised use.

Adverse effects and risks

Acute effects of psilocybin include anxiety, fear, perceptual changes, nausea, headache, increased blood pressure and increased heart rate. During difficult experiences, panic, transient paranoia or disorganization may occur. A controlled environment and trained staff reduce the risk of dangerous behavior during the altered state but do not eliminate the possibility of intense psychological events.

The possibility of mania or psychosis is a particular concern in vulnerable individuals and explains the frequent exclusion of such patients from studies. Rare persistent perceptual disturbances after hallucinogen use have been described; their frequency in modern clinical protocols is uncertain. Suicidal events observed in some treatment-resistant depression programs require careful monitoring and prevent the assumption that a rapid antidepressant effect is equivalent to protection from suicide.

The abuse potential of classic psychedelics differs from that of substances with stronger dopaminergic reinforcement, but this does not make unsupervised use safe. Uncertain purity, unpredictable dosing, drug combinations, an unprotected setting and lack of screening can substantially increase risk.

• Clinical research concerns substances of pharmaceutical quality and defined doses, not mushrooms or preparations of uncertain composition.
• Bipolar or psychotic vulnerability requires particular caution and often results in exclusion from trials.
• An intense subjective experience does not by itself demonstrate an antidepressant response.
• Self-administration is not equivalent to psychedelic-assisted treatment studied in a clinical setting.

Regulatory status and outlook

As of August 19, 2026, psilocybin for depression remains an investigational treatment in the United States. Expedited designations, priority programs or positive results from advanced studies are not equivalent to approval and do not by themselves establish a favorable benefit-risk ratio in clinical practice. The FDA’s 2026 final guidance specifically addresses development, safety, control and interpretation issues in psychedelic-drug studies.

Future prospects will depend on late-phase trials, independent replication, definition of the role of psychological support, large-scale safety data, maintenance strategies and sustainable care models. If a formulation is authorized, the indication will apply to that product and regulatory protocol, not to the entire category of psychedelics.

The scientifically appropriate conclusion therefore lies between enthusiasm and rejection: psilocybin has produced robust antidepressant signals in several controlled trials and represents one of the most promising areas of contemporary psychopharmacology, but it remains necessary to distinguish experimental evidence, regulatory approval and standard clinical practice.

Status varies among countries and may include clinical research, special access or local regulatory frameworks, but none of these conditions should be confused with approval of an antidepressant product for general use. Even in the future, any authorization will need to be interpreted in terms of formulation, dose, population, setting and administration requirements. Regulation is particularly relevant because the intense subjective experience requires drug quality control, emergency management and specific clinical expertise. Scientific innovation therefore does not eliminate the need for pharmacovigilance, registries, professional standards and post-marketing studies capable of identifying rare events and real-world outcomes.

Bibliography
1. Raison CL et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 330(9), 2023: 843-853.
2. Goodwin GM et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine. 387(18), 2022: 1637-1648.
3. Davis AK et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 78(5), 2021: 481-489.
4. Carhart-Harris R et al. Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine. 384(15), 2021: 1402-1411.
5. Rosenblat JD et al. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med. 5(3), 2024: 190-200.e5.
6. Carhart-Harris RL et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 3(7), 2016: 619-627.
7. Carhart-Harris RL et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 235(2), 2018: 399-408.
8. Gukasyan N et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology. 36(2), 2022: 151-158.
9. Palhano-Fontes F et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological Medicine. 49(4), 2019: 655-663.
10. Haikazian S et al. Psilocybin-assisted treatment for depression: A systematic review and meta-analysis. Psychiatry Research. 329, 2023: 115531.
11. Rucker JJ et al. Psychedelics in the treatment of unipolar mood disorders: a systematic review. Journal of Psychopharmacology. 30(12), 2016: 1220-1229.
12. Hosein MM et al. Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds. EClinicalMedicine. 89, 2025: 103517.